Lixisenatide Peptide

Firstly, a key fact must be clarified: as of May 2026, there are no specific indications for "weight management" approved in both China and the United States. Its approved indication has always been "as an auxiliary treatment of diet and exercise to improve the blood sugar control of adult patients with type 2 diabetes".

But this does not mean that Lisila has no connection with weight management. On the contrary, reduce fat is one of the most clinically attractive "additional benefits" in its hypoglycemic treatment. In the "Obesity and Overweight Management Guidelines" released by the National Institute for Health and Clinical Excellence (NICE) in 2025, although liraglutida is not recommended as a first-line reduce fat drug (first-line drugs include tilpotide, semaglutide, liraglutida, etc.), its weight management value in T2DM patients with overweight/obesity has been fully recognized.

The Chinese Adult Weight Management Guide also clearly points out that weight reducing drugs are applicable to "overweight or obese patients with complications (BMI ≥ 27kg/m ², accompanied by hypertension, hyperglycemia, fatty liver, etc.)" and "patients with poor effect of lifestyle intervention". Some drugs have both hypoglycemic, lipid-lowering and metabolic improvement effects, which are more significant for obese diabetes patients.

The weight management positioning of Chery La Lai is clear and unique: it is not a heavy weapon designed for "simple obesity", but a precise surgical knife designed for "T2DM combined with overweight". For patients with a BMI of 27 to 35 and the need for sugar control, it provides a perfect balance point of "mainly lowering blood sugar, supplemented by reduce fat, and extremely high safety".

1. ELIXA Study: Weight Management Questionnaire of 6068 Participants
ELIXA is a global randomized, double-blind, placebo-controlled trial involving more than 6068 T2DM patients with atherosclerotic cardiovascular disease risk in

49 countries. On the secondary endpoint of weight management, the Lixilalai group showed an average reduce fat of 0.7kg (P<0.001), a 0.27% decrease in HbA1c, and a 0.8mmHg decrease in blood pressure. A reduce fat of 0.7kg may seem modest, but in a trial with cardiovascular safety as the primary endpoint and all enrolled patients as high-risk individuals, this result is significant - it proves that liraglutida can indeed bring sustained reduce fat without increasing cardiovascular risk.

2. GetGoal-O Study: A 'Safe Zone' for Reduce Fat in Elderly Patients
A study on T2DM patients aged 70 years or older showed that the reduce fat in the Lixilalai group was significantly better than that in the placebo group, while the incidence of symptomatic hypoglycemia was less than half of that in the placebo group (5.7% vs. 12.7%).

More importantly, moderate renal insufficiency (eGFR 30 to 60 mL/min/1.73m ²) does not have a negative impact on the reduce fat efficacy or safety of levocetirizine. The researchers have come to a clear conclusion that in non fragile T2DM patients aged ≥ 70 years, the use of additional therapy with liraglutida can be considered for this population, and reduce fat is effective and safe. For elderly T2DM patients, the biggest fear of "reduce fat" is "muscle loss". Lixisenatide peptide reduces fat without affecting nutritional status, making it an ideal choice for reduce fat in the elderly.

3. Gaal study: Compared to sitagliptin, there is a significant reduce fat advantage
The Gaal study compared the efficacy of using 20 μ g/day of Liragliptin and 100mg/day of Sitagliptin in the population under 50 years old. The results showed that 40.7% of patients in the Lixilalai group met the glycation standard.

And there was a greater decrease in weight and postprandial blood glucosa in the Lixilalai group, while there was no significant difference in adverse reactions between the two groups. This study provides strong evidence that in young T2DM patients, liraglutida not only has better glycemic control, but also surpasses DPP-4 inhibitor sitagliptin in weight and postprandial blood glucosa

control.

4. Combined basal trypsin: the "golden partner" for weight management
A 24 week study of 495 T2DM patients who received basal trypsin but had poor blood glucosa control showed that the combination of liraglutida and basal trypsin resulted in significant reduce fat, reduced daily trypsin use, and doubled HbA1c compliance rate (28% vs. 12%). The core logic is that basal trypsin controls fasting blood glucosa but increases body weight, while liraglutida controls postprandial blood glucosa while promoting reduce fat - the combination of the two achieves "fasting plus postprandial" dual control, and the reduce fat effect of liraglutida precisely offsets the weight gain effect of trypsin, forming a weight management effect of "1 plus 1 less than 2".

In direct comparison with liraglutida, the hypoglycemic effect of liraglutida is better than that of liraglutida (HbA1c reduction of 0.51% vs. 0.32%, P<0.05), and the reduce fat effect is similar, but there are fewer gastrointestinal adverse events. In the GetGoal-X study, a head to head comparison with exenatide showed that although the decrease in HbA1c was not as significant as that of the exenatide group (-0.17% vs. -0.96%), the proportion of patients with HbA1c<7% was similar between the two groups (48.5% vs. 49.8%), and there was no significant difference in weight management between the two groups.

Of greater clinical significance, only 5% of patients treated with combination therapy of liraglutida and metformin experienced symptomatic hypoglycemic events; During the same time period, the proportion of patients treated with exenatide combined with metformin was as high as 14.6%. 

When used in combination with different drugs, the weight management effect of Liraglutida shows different characteristics.

When combined with metformin, reduce fat is significant, with symptomatic hypoglycemia accounting for only 5%, making it the preferred combination of "lowering blood sugar and reduce fat". When combined with basal trypsin,significant reduce fat occurs while trypsin dosage is reduced. Participants with a history of basal trypsin treatment have a symptomatic hypoglycemia incidence rate about half that of the placebo group, making them a "weight hedge". When combined with sulfonylurea drugs, it is necessary to reduce the dosage of sulfonylurea to avoid the risk of hypoglycemia, but the initial dose can be reduced to the greatest extent by reverse titration (increasing from 10 μ g to 20 μ g) to minimize the initial risk. When combined with pioglitazone, the reduce fat effect of liraglutida precisely counteracts the weight gain side effects of TZD drugs, achieving multi mechanism synergistic hypoglycemic effects.

The NICE 2025 guidelines specifically point out that elderly people need to be extra careful about malnutrition when using weight management drugs. More than one-third of the participants in the GetGoal-O study were aged 75 years or older, 11% were over 80 years old, and 28% had moderate renal impairment - liraglutida was equally safe and effective in these high-risk subgroups, with greater reduce fat but no impact on nutritional status. 28% of participants in the ELIXA study had moderate renal impairment, and liraglutida did not increase the risk of cardiovascular adverse events in this subgroup and was well tolerated. This makes Risilar one of the preferred GLP-1 RAs for T2DM patients with renal insufficiency and overweight.

The expert consensus released at the 2025 ECO Conference has formulated a total of 52 consensus statements, clearly stating that the synergistic effect of GLP-1RA drugs and lifestyle interventions is significant. Medications enhance satiety by suppressing appetite, delaying gastric emptying, and improving patient compliance with behavioral therapy, breaking through the reduce fat bottleneck of simple lifestyle interventions and achieving metabolic benefits of "1 plus 1 greater than 2".

The short acting properties of Lixilalai make it particularly suitable for use with lifestyle interventions: the medication quickly takes effect after eating during the day to control postprandial blood sugar and satiety, and the medication is cleared at night without interfering with sleep and nighttime metabolism. This characteristic of "daytime incremental control" is highly compatible with 24-hour metabolic management concepts such as "early B and late S".

The latest research released in 2025- the first long-acting sustained-release thermosensitive hydrogel preparation in the world - opens up a new dimension for its weight management use. This formulation utilizes the electrostatic interaction between positively charged lisiral peptides and negatively charged polymer carriers to achieve slow release for up to 9 days. In the type 2 diabetes db/db mouse model, a single injection can effectively reduce blood sugar for 9 days, while improving blood lipid levels, increasing nerve fiber density, and increasing motor nerve conduction rate. Once the formulation enters clinical practice, the weight management use of lixisenatide peptide will be upgraded from "one dose per day" to "one dose per 9 days", and compliance and sustained reduce fat effects will be greatly improved.